Skip to main content

The impact of a low-calorie, low-glycemic diet on systemic lupus erythematosus: a systematic review

Abstract

Background

Diet plays a critical role in Systemic Lupus Erythematosus (SLE) patients, impacting on the microbiota composition and, consequently, on the immune response. The objective was to analyze and verify the diet effect on SLE patients.

Methods

This is a systematic review performed at the Evidences-based Health Lab, Escola Superior em Ciências da Saúde, Brasília (DF), Brazil. In March, 2021, five databases, and grey literature, through JSTOR, Open Grey, and Google Scholar were searched. Randomized Clinical Trials in which SLE patients with calorie restricted, low glycemic index or other diet involving the joint adequacy of these aspects, compared with placebo or different types of diet, were included.

Results

It was identified in the databases 758 articles; 132 were duplicated; 616 references were screened, and 604 were excluded. After reading the title and abstract, 12 articles were included for full-text reading. After the full-text reading, three studies were included for quantitative analysis. The diet improved the quality of life at 6 (MD 16.30; 5.91;26.69) and 12 weeks (MD 14.60; 0.88;28.32). The GRADE was used to evaluate the quality of evidence.

Conclusion

There is low evidence that the diet has a positive impact on the quality of life of SLE patients.

Trial registration PROSPERO—CRD4202012208.

Introduction

Systemic lupus erythematosus (SLE) can be defined as a chronic autoimmune disease with varied, complex clinical manifestations [1]. According to the Lupus Commission of Brazilian Society of Rheumatology, it is an estimated prevalence of 65,000 people diagnosed with systemic lupus erythematosus in Brazil [2]. The incidence is higher in women, 1 in 1,700. In a systematic review (SR) of epidemiological studies by Rees et al. [3], the highest world incidence was verified in North America and the lowest in Africa. Furthermore, in most studies, European countries showed the lowest incidence, while Asia, Australia, and America showed the highest rates. It should be stressed that incidences may be associated with places where studies are more frequently conducted or more availability of treatment is confirmed.

Immune system activation in SLE is characterized by exaggerated B-cell and T-cell responses and loss of immune tolerance against self-antigens, contributing to several clinical manifestations, the most common are fatigue, loss of appetite and weight, skin lesions (mainly malar rash), arthritis, serositis (pleuritis and/or pericarditis), kidney or central nervous system involvement and hematological manifestations (cytopenias) associated with various autoantibodies, particularly antinuclear antibodies [4, 5].

Considering cardiovascular aspects, systemic lupus erythematosus patients have an increased risk of developing atherosclerosis, hypertension, dyslipidemia, and obesity [6, 7]. The characteristic of dyslipidemia is the increase in total cholesterol, low-density lipoprotein (LDL), and triglyceride, with a decrease in high-density lipoprotein (HDL) [8]. The continued use of corticosteroids is a contributing factor to increased cardiovascular risk [7].

There is an increasing number of studies, still inconclusive, that evaluate the antioxidant, anti-inflammatory, and immunomodulatory effect through dietary therapy in the prevention and management of symptoms and comorbidities of patients with SLE [9].

Environmental factors can influence and modulate the onset and progression of systemic lupus erythematosus. Among those, diet plays a critical role, impacting the microbiota composition and, consequently, the immune response. There are a degree and type variation of such immune response, which depends on genetic and additional factors, such as stress, lifestyle, and medication [10]. The objective of nutritional intervention is to provide bodyweight control and a decrease in calories, saturated fat, and total fat intake. The decision to perform the present systematic review was based on the high frequency of risk factors for cardiovascular involvement in systemic lupus erythematosus patients and on the importance of analyzing and verifying the diet effect on the disease activity, as well as on the lipid parameters.

Objective

To verify the diet impact on systemic lupus erythematosus patients.

Methods

Type of study

The present study consists of a systematic review of the literature. The research question was: "What is the diet effect on systemic lupus erythematosus patients?" This study's protocol was registered on the International Prospective Register of Systematic Reviews—PROSPERO (www.crd.york.ac.uk/PROSPERO/) under number CRD42020122089.

The basic protocol was defined in April 2019, and the search strategy, eligibility criteria, bias, and outcome assessment instrument were established. Subsequently, the systematic review was registered in PROSPERO, and due to the great demand for orders and required changes, the definitive answer came only in March 2020.

Inclusion criteria

Type of patient: systemic lupus erythematosus patients, with no age and gender restriction.

Type of intervention: Calorie restricted (Low Cal), low glycaemic index (Low GI) or other diet involving the joint adequacy of these aspects.

Control: Placebo or different types of diet.

Outcome: Questionnaires and scores to evaluate the disease activity, fatigue, quality of sleep, quality of life, and lipid profile parameters.

Type of study: Randomized clinical trials.

Exclusion criteria

Studies that investigate omega-3, calcium, or any other type of supplementation were not included in this research.

Searched databases

An extensive article search was conducted in March 2021 with no language and timeframe limitations. The databases searched were: The Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, EMBASE, PubMed, SCOPUS, Web of Science, LILACS, and grey literature, through JSTOR, Open Grey, and Google Scholar. The keywords provided in the Medical Subject Headings (MeSH) were used to develop the primary search strategy and applied in PubMed. When words allowing different spellings were found, the synonyms appearing in MeSH were used. This strategy was adapted for the other databases. In LILACS, the same keywords in Spanish and English were used. See Table 1 for the applied search strategy. Manual research on relevant articles reference list was also done.

Table 1 Database search strategy

Study selection

After the search was completed, the studies found were entered on COVIDENCE (https://www.covidence.org/home), and two independent reviewers performed the study selection (AMI and HES). The first selection filter was based on title and abstract and then on full text. There was no need for a third reviewer to resolve disagreements.

Data extraction and data analyses

For continuous data, the mean and standard deviation were extracted from the included studies. For the binary data, the number of events was extracted.

For the meta-analysis, the random-effects model would be used to estimate the effect of diet on the evaluated outcomes. For binary data, a risk ratio (RR) with a 95% confidence interval (CI) was used to assess the effect size. The risk difference between the intervention and control groups was calculated according to the Cochrane Collaboration handbook through the following calculus: 100 × (1 − RR)%. Continuous data were evaluated through mean with a 95% CI. Due to the data heterogeneity, the meta-analysis was not possible to be performed; however, the effect size of the collected data was estimated with a 95% CI and are presented in Table 2. Based on the Cochrane Collaboration handbook, for data interpretation, not only the statistical significance was considered, but also the change in the outcomes, which may not be relevant to the statistical aspect, but is relevant to the clinical aspect.

Table 2 Summary of descriptive characteristics of included articles (n = 3)

Unit of analysis issues

The unit of analysis was individual patients.

Dealing with missing data

In case of missing data, the authors of the studies would be consulted. However, it was not necessary, as the studies provided quantitative data.

Studies summary

The studies were summarized per author, publishing date, country, and place of study, intervention performed and results obtained.

Risk of bias assessment and GRADE approach

Through the Cochrane Collaboration risk-of-bias tool, the following domains were evaluated: random sequence generation, allocation sequence concealment, blinding of participants and personnel, blinding of reviewer, missing data, outcome selection, and other biases. Biases in texts included in the studies selection were identified. The risk of bias was evaluated by two independent reviewers (AMI and HES). There was no need for a third reviewer to resolve disagreements. The data was extracted from the selected articles, and the answers were classified using parameters of "yes", for low risk of bias; "no", for high risk of bias; and "unclear", for unknown or obscure risk of bias. The GRADE approach three domains and other considerations were used to grade the evidence for the main outcomes.

Outcomes

The potential significant outcomes were the evaluation of:

  • Lipid profile parameters: High-density lipoprotein, Low-density lipoprotein, Triglyceride, Glycemic index)

  • Disease activity, assessed with the Global activity by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), British Isles Lupus Assessment Group (BILAG), and European Community Lupus Activity Measure (ECLAM).

  • Quality of life assessed with Lupus Quality of Life (LupusQoL), SLE-specific Quality of Life questionnaire (SLEQoL), SLE Quality of Life Questionnaire (L-QoL)), or another questionnaire with the same purpose.

  • Quality and efficiency of sleep

  • Fatigue with Fatigue Severity Scale (FSS).

The potential minor outcome was adherence to the diet.

Results

It was identified in the databases 758 articles; 132 were duplicated (Fig. 1); 616 references were screened, and 604 were excluded. After reading the title and abstract, 12 articles were included for full-text reading. After the full-text reading, three studies were included for quantitative analysis. The reasons for the exclusion of nine articles from the study were: Alternative Treatments – antiseptics, antibiotics, supplementation (n = 7); Cross-sectional, case–control, cohort studies, or any interventional design other than randomized clinical trials (n = 2).

Fig. 1
figure 1

PRISMA Flow diagram of literature searched and selection criteria

The three articles included for the quantitative analysis were written in the United States (n = 1), in Brazil (n = 1), and in the United Kingdom (n = 1) in 2002, 2012, and 2018, respectively. The sample size varied between 17 and 31 people diagnosed with systemic lupus erythematosus. The description of these studies is shown in Table 3.

Table 3 Post-intervention values of estimated effects for all outcomes evaluated

Sample characteristics

Silva et al [11]. included adolescents diagnosed with systemic lupus erythematosus for at least six months, with any clinical manifestation and disease activity. Shah et al. [8] and Davies et al. [7] included only women diagnosed with systemic lupus erythematosus for at least six months. In the study by Davies et al. [7] there was no difference between the groups in the number of patients with hypertension and hyperlipidemia, nor was the number of caucasians and non-caucasians similar between the groups. Shah et al. [8] found that African American were 60% of both groups and the remainder, predominantly of Hispanic origin.

Medication used by patients

Regarding the use of medication, in the studies by Davies et al. [7] and Silva et al. [11], there was no significant difference between the groups in terms of prednisolone dosage and hydroxychloroquine users. Shah et al. [8] found that prednisolone use was slightly higher in the control group but without significant difference. In addition, four patients in the diet group and five patients in the control group were using cholesterol-lowering medication.

Diet types

The study conducted by Silva et al. [11] researched diet based on general behavioural guidelines, healthy eating, food diversity, balanced intake of fat and carbohydrate, and adequate intake of salt, fruit, vegetables, omega-3, and fibres. Additionally, orientations on lifestyle, frequency of meals, and physical activities were also analyzed. The controlled nutritional intervention study lasted nine months.

Shah et al. [8] followed the National Cholesterol Education Program Step 2 diet: 30% or less calories from fat (7% from saturated fat, 13% from monounsaturated fat, and 10% from polyunsaturated fat), and < 200 mg of cholesterol per day. The diet intervention lasted for 12 weeks.

Davies et al. [7] compared two diet types. One diet type limited the carbohydrate intake to 45 g per day, without restricting the consumption of fat and protein. The composition of this diet was 10–15% of daily calories from carbohydrate, 25% from protein, and 60% from both saturated and unsaturated fat. The other was a calorie-restricted diet with limitation of 2000 kcal per day, approximately 50% from carbohydrates, 15% from protein, and 30% from fat.

Diet effects compared to control

Quality of life

Shah et al. [8] evaluated the quality of life using a self-administered questionnaire. The diet produced a small contribution to the quality of life improvement at six weeks (mean difference (MD) 16.30; 95% confidence interval (CI) 5.91; 26.69) and 12 weeks (MD 14.60; 95% CI 0.88; 28.32). There was statistically significant difference in both times of evaluation.

Disease activity

Silva et al. [11] evaluated the disease activity through Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2 K > 4. There was no relevant difference between both groups (RR 1.07; 95% CI − 0.32–3.52). There was no statistically significant difference.

Lipid profile at six weeks

Shah et al. [8] evaluated the lipid profile at six weeks. Although the diet caused a small improvement in the lipid profile of high-density lipoprotein (MD − 5.50; 95% CI − 18.21; 7.21), low-density lipoprotein (MD 5.70; 95% CI − 16.72; 28.12), and triglyceride (MD − 2.50; 95% CI − 70.67; 65.67), there was no statistically significant difference.

Lipid profile at 12 weeks

Shah et al. [8] evaluated the lipid profile at 12 weeks. The diet caused an improvement in the lipid profile of high-density lipoprotein (MD − 3.90; 95% CI − 17.54; 9.74), low-density lipoprotein (MD 15.30; 95% CI − 8.12; 38.72), and triglyceride (MD − 13.40; 95% CI − 50.27; 23.47), however, there was no statistically significant difference.

Lipid profile at nine months

Silva et al. [11] evaluated the lipid profile at nine months. The low calorie diet was favorable for the improvement in high-density lipoprotein (MD 4.30; 95% CI − 6.96; 15.56 P = 0.45), low-density lipoprotein (MD − 13.15; 95% CI − 29.38; 3.08 P = 0.11), and triglyceride (MD 11.30; 95% CI − 16.90; 39.50 P = 0.43), however, there was no statistically significant difference.

Comparison between the low glycemic index diet and the calorie-restricted diet

Evaluation of disease activity, fatigue, and quality of sleep

Davies et al. [7] evaluated the lipid profile at six weeks. The diet type did not affect the evaluation of fatigue, through the Fatigue Severity Scale (FSS) (MD 0.00; 95% CI − 1.20; 1.20 P = 0.00); disease activity, through the British Isles Lupus Assessment Group (BILAG) (MD 0.00; 95% CI − 3.52; 3.52 P = 1.00); and quality of sleep, case on which it had small impact (MD 0.00; 95% CI − 3.52; 3.52 P = 1.00). Although there was no statistically significant difference, by evaluating the disease activity through the European Community Lupus Activity Measure (ECLAM), the low glycemic index diet showed a favourable effect (MD 0.90; 95% CI − 1.94; 0.14 P = 0.09).

Lipid profile analyses

Silva et al. [11] evaluated the lipid profile at six weeks. The low glycemic index diet was favorable for the improvement in high-density lipoprotein (MD − 0.24; 95% CI − 0.48; − 0.00 P = 0.05), low-density lipoprotein (MD − 1; 95% CI –1.60; − 0.40 P = 0.001), and triglyceride (MD − 0.35; 95% CI − 0.89; 0.19 P = 0.20). There was no statistically significant difference in the low-density lipoprotein evaluation (P = 0.0001).

Risk of bias and quality of evidence

None of the studies met all methodological quality criteria. Two studies did not describe the concealment of the allocation sequence [7, 8], and none of the studies described the blinding of participants and personnel as determined by the Risk of Bias instrument used.

Three studies were considered to have a low risk of bias for incomplete outcomes and did not report the main predetermined result [7, 10]. However, they were deemed to be free of other problems that could lead to a high risk of bias.

Quality of life, disease activity, and lipid profile outcomes at both 12 weeks and 9 months were selected and described as main outcomes in Table 4. Based on the risk of bias assessment and the GRADE approach three domains, it was found that through the evaluated outcomes, the level of evidence for the impact of diet on systemic lupus erythematosus patients is low (Fig. 2).

Table 4 Summary of findings
Fig. 2
figure 2

Risk of bias assessment of included studies

Discussion

The present study verified that the diet had a positive impact on the quality of life, and lipid profile of systemic lupus erythematosus patients. Three randomized controlled trials (RCTs) were included; however, due to the heterogeneity of the studies in relation to the control group and the moment of evaluation, it was not possible to perform the data meta-analysis. Nonetheless, to verify the effect size of interventions and compare it among the groups, the data presentation of choice was by effect size estimation.

According to Shah et al. [8], the diet intervention presented a small effect on the quality of life improvement. The questionnaire used by the authors assessed the general energy level, ability to perform specific tasks, quality of sleep, satisfaction with food eaten, satisfaction with personal life, relationships, etc. According to Chaigne et al. [12], musculoskeletal involvement, socio-demographic factors, fatigue, and comorbidities are directly related to the quality of life of systemic lupus erythematosus patients and can be modified when subjected to a controlled diet.

The European League Against Rheumatism (EULAR) stated that the quality of life-related to health is an important parameter and should be continuously evaluated in the clinical routine. Regarding the quality of life, the authors did not attribute a slight improvement to the diet itself, but the intensity of counselling received by patients in the intervention group.

The disease activity assessed by Systemic Lupus Erythematosus Disease Activity Index 2 K > 4 at the end of the study conducted by Silva et al. [11], which lasted for six months, did not show any relevant difference between the group submitted to the diet and the control group. According to the authors, the groups did not differ regarding the corticoid dose used throughout the study. The authors observed that there was a significant change in the intervention group, with a reduction in the carbohydrate, saturated fat, trans and total fat, and calories intake. There was no change in the body mass index among participants in the intervention group, but when compared to the control group, these participants presented a weight gain. As the adipose tissue secretes pro-inflammatory cytokines, the increased adipose mass may contribute to the inflammation worsening, which may justify the disease activity worsening in the control group [13].

The subject is still controversial, but there is a suggestion that obesity and a high-fat diet are related to SLE, with the frequency of obesity being higher in SLE patients than in the general population. Vitamin D deficiency and increased adipokines, such as leptin and adiponectin, may explain the relationship between obesity and SLE [14].

Regarding the lipid profile, the study conducted by Shah et al. [8] showed that the diet improved the high-density lipoprotein, low-density lipoprotein, and triglyceride levels at both 6 and 12 weeks, which was more accentuated at 12 weeks. Silva et al. [11] showed an improvement in high-density lipoprotein, low-density lipoprotein, and triglyceride levels in adolescents at the 9-month evaluation. The results of both studies prove the effectiveness of protecting the cardiovascular system through diet and that adults and adolescents adhered to the proposed diet. For involving adolescents, the study conducted by Silva et al. [11] proves that the diet can be effective even among groups that are usually resistant to changing habits [15]. According to the Update of the Brazilian Guideline on Dyslipidemias and Prevention of Atherosclerosis, the control of saturated fat intake and its substitution with polyunsaturated fatty acids, precepts followed in both studies, are associated with cholesterol total and low-density lipoprotein cholesterol decrease, as well as with a decrease in cardiovascular events and death [16].

The comparison between the diets was also enabled by Davies et al. study [7], which compared the low glycemic index and calorie-restricted diets. As for the lipid profile, Davies et al. [7] verified that none of the groups presented a significant index reduction when compared to the initial evaluation. However, when the data was inserted in the forest plot, it shows that the low glycemic index diet was more favourable for high-density lipoprotein, low-density lipoprotein, and triglyceride improvement than the calorie-restricted diet. The type of diet did not affect the fatigue, quality of sleep, and disease activity as assessed through the British Isles Lupus Assessment Group. However, when the European Community Lupus Activity Measure evaluated the low glycemic index diet, its effect was favourable on fatigue. The study conducted by Davies et al. [7] shows that the low glycemic index diet redresses the postprandial hyperglycemia and hyperinsulinemia and the late postprandial hypoglycemia, which increases the risk of obesity, diabetes, and cardiovascular disease. The Update of the Brazilian Guideline on Dyslipidemias and Prevention of Atherosclerosis indicates as an adequate strategy for handling dyslipidemia diets such as the Mediterranean diet, emphasizing the importance of keeping a moderate-fat quantity, eliminating trans fatty acids, controlling the consumption of saturated fats, prioritizing polyunsaturated and monounsaturated fats, reducing sugars, and including lean meats, fruits, grains, and vegetables in the diet [16]. It further stresses that high carbohydrate intake increases glycemia, which generates hyperinsulinemia. In turn, this condition activates the transcription factors that promote the synthesis of fatty acids and triglycerides. There is still no substantial evidence proving the effectiveness of the low carbohydrate diet on lipid profile, mainly because the studies diverge significantly on the low carbohydrate diet definition. The 2018 United Kingdom guidelines on diabetes show that long-term adherence to low carbohydrate diets is low [17].

It has been demonstrated in studies that medications such as hydroxychloroquine and prednisone may affect the lipid profile [18, 19]. Hydroxychloroquine seems to have a beneficial effect due to the reduction of atherogenic lipoproteins and prednisone is associated with a worsening in the lipid profile of patients with lupus activity [18]. The studies included in this review did not differ between groups regarding the use of hydroxychloroquine and prednisone. It is important to note that the review evaluated patients with inactive disease and, probably, with low doses of these drugs.

Medeiros et al. [] published a systematic review investigating the effects of nutritional supplements such as omega-3 and vitamin D, as well as the study by Islam et al. who recommends intake of Omega 3 and 6; vitamins A, B, C, D, and E; minerals (calcium, zinc, selenium, iron, and copper) and polyphenol-containing foods to produce an immunomodulatory effect in SLE patients [21], differing from the present study because the objective of the latter was to evaluate the nutritional diet impact, not a specific nutritional supplement. Regarding methodological aspects, the review by Medeiros et al. [] restricted the search to the period from 2006 to 2016, and the exclusion criteria evaluated nutrients or diet analyses only. Furthermore, the systematic review did not describe the results regarding the effectiveness of the interventions.

Supplementation of macronutrients and micronutrients produces immunomodulatory effects in SLE patients, so the intake of Omega 3 and 6, vitamins A, B, C, D, and E, minerals such as calcium, zinc, selenium, iron, and copper, and polyphenol-containing foods are recommended.

Because dietary supplementation of various macro and micronutrients have exhibited immunomodulatory effects, including maintenance of homeostasis and improved physical and mental well-being in SLE patients, it is recommended that these patients consume a balanced diet that is low in calories and protein but contains plenty of fiber, PUFAs (ω3 and ω-6), vitamins (A, B, C, D, and E), minerals (calcium, zinc, selenium, iron, and copper), and polyphenol-containing foods.

The present systematic review is the first study about the nutritional diet impact on systemic lupus erythematosus patients and followed the methodological principles considered essential to conduct and report a systematic review, which includes conducting searches in several databases without date and language restriction, evaluating and selecting articles independently, and registering the protocol on PROSPERO.

Some limitations were found in this review. The small number of included studies and the small number of patients included can lead to a conclusion that does not correspond to reality. The different types of diets evaluated makes it difficult to standardize the studied intervention. This problem can be overcome by conducting studies with the involvement of several centres in a multicenter way. Also, the heterogeneity of the data makes it impossible to carry out a meta-analysis. Due to these limitations, further studies are needed to confirm the association between the impact of diet on patients with systemic lupus erythematosus.

Conclusions

Regarding its implication for the practice, studies such as the present systematic review help to promote public policies focusing on the population with rare and chronic diseases such as systemic lupus erythematosus. As for its implication for research, being the proposed interventions safe and effective, it should encourage researches aimed at verifying the outcome of the specific nutritional diet implementation in systemic lupus erythematosus patients.

The diet had a positive impact on the quality of life and a possible clinical relevance on lipid profile (high-density lipoprotein, low-density lipoprotein, triglyceride levels) of systemic lupus erythematosus patients. Both types of diet, calorie-restricted and low glycemic index did not influence disease activity, fatigue and quality of sleep outcomes. Based on GRADE approach, the evidence level for all outcomes was considered low.

Availability of data and materials

Not applicable.

References

  1. Zucchi D, Elefante E, Calabresi E, et al. One year in review 2019: systemic lupus erythematosus. Clin Exp Rheumatol. 2019;37(5):715–22.

    PubMed  Google Scholar 

  2. Lupus Commission. Systemic lupus erythematosus (SLE): BSR primer. Brazilian Society of Rheumatology. 2011. http://reumatologia.org.br/orientacoes-ao-paciente/lupus-eritematoso-sistemico-les-cartilha-da-sbr. Accessed 08 Oct 2020.

  3. Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017;56(11):1945–61. https://doi.org/10.1093/rheumatology/kex260.

    Article  Google Scholar 

  4. Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med. 2020;172(11):ITC81–96. https://doi.org/10.7326/AITC202006020.

    Article  PubMed  Google Scholar 

  5. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86. https://doi.org/10.1002/art.34473.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Klack K, Bonfa E, Borba Neto EF. Diet and nutritional aspects in systemic lupus erythematosus. Rev Bras Reumatol. 2012;52(3):384–408. https://doi.org/10.1590/S0482-50042012000300009.

    Article  PubMed  Google Scholar 

  7. Davies RJ, Lomer MC, Yeo SI, et al. Weight loss and improvements in fatigue in systemic lupus erythematosus: a controlled trial of a low glycaemic index diet versus a calorie restricted diet in patients treated with corticosteroids. Lupus. 2012;21(6):649–55. https://doi.org/10.1177/0961203312436854.

    Article  CAS  PubMed  Google Scholar 

  8. Shah M, Kavanaugh A, Coyle Y, Adams-Huet B, Lipsky PE. Effect of a culturally sensitive cholesterol lowering diet program on lipid and lipoproteins, body weight, nutrient intakes, and quality of life in patients with systemic lupus erythematosus. J Rheumatol. 2002;29(10):2122–8.

    CAS  PubMed  Google Scholar 

  9. Aparicio-Soto M, Sánchez-Hidalgo M, Alarcón-de-la-Lastra C. An update on diet and nutritional factors in systemic lupus erythematosus management. Nutr Res Rev. 2017;30(1):118–37. https://doi.org/10.1017/S0954422417000026.

    Article  PubMed  Google Scholar 

  10. La Cava A. The influence of diet and obesity on gene expression in SLE. Genes (Basel). 2019;10(5):405. https://doi.org/10.3390/genes10050405.

    Article  CAS  Google Scholar 

  11. da Silva SGL, Terreri MT, Abad TTO, et al. The effect of nutritional intervention on the lipid profile and dietary intake of adolescents with juvenile systemic lupus erythematosus: a randomized, controlled trial. Lupus. 2018;27(5):820–7. https://doi.org/10.1177/0961203317751851.

    Article  CAS  PubMed  Google Scholar 

  12. Chaigne B, Chizzolini C, Perneger T, et al. Impact of disease activity on health-related quality of life in systemic lupus erythematosus—a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). BMC Immunol. 2017;18(1):17. https://doi.org/10.1186/s12865-017-0200-5.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc. 2001;60(3):349–56. https://doi.org/10.1079/pns2001110.

    Article  CAS  PubMed  Google Scholar 

  14. Kono M, Nagafuchi Y, Shoda H, et al. The impact of obesity and a high-fat diet on clinical and immunological features in systemic lupus erythematosus. Nutrients. 2021;13(2):504. https://doi.org/10.3390/nu13020504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ho M, Garnett SP, Baur L, et al. Effectiveness of lifestyle interventions in child obesity: systematic review with meta-analysis. Pediatrics. 2012;130(6):e1647–71. https://doi.org/10.1542/peds.2012-1176.

    Article  PubMed  Google Scholar 

  16. Faludi AA, Izar MCO, Saraiva JFK, et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017. Arq Bras Cardiol. 2017;109(2 Supl 1):1–76. https://doi.org/10.5935/abc.20170121.

    Article  PubMed  Google Scholar 

  17. Dyson PA, Twenefour D, Breen C, et al. Diabetes UK evidence-based nutrition guidelines for the prevention and management of diabetes. Diabet Med. 2018;35(5):541–7. https://doi.org/10.1111/dme.13603.

    Article  CAS  PubMed  Google Scholar 

  18. Cairoli E, Rebella M, Danese N, Garra V, Borba EF. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus. 2012;21(11):1178–82. https://doi.org/10.1177/0961203312450084.

    Article  CAS  PubMed  Google Scholar 

  19. Sarkissian T, Beyene J, Feldman B, McCrindle B, Silverman ED. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum. 2007;56(2):631–8. https://doi.org/10.1002/art.22332.

    Article  CAS  PubMed  Google Scholar 

  20. Durcan L, Winegar DA, Connelly MA, et al. Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy. J Rheumatol. 2016;43(4):745–50. https://doi.org/10.3899/jrheum.150437.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Islam MA, Khandker SS, Kotyla PJ, Hassan R. Immunomodulatory effects of diet and nutrients in systemic lupus erythematosus (SLE): a systematic review. Front Immunol. 2020;11:1477. https://doi.org/10.3389/fimmu.2020.01477.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Fundação de Ensino e Pesquisa em Ciências da Saúde (00064-0000417/2018-52).

Author information

Authors and Affiliations

Authors

Contributions

Conceptua Imoto AM lization (lead), data curation (lead), formal analysis (lead), funding acquisition (lead), methodology (lead), project administration (lead), supervision (lead), validation (lead), visualization (lead), writing-original draft (lead), writing-review and editing (lead); Gottems L: funding acquisition (supporting), writing-original draft (supporting), writing-review and editing (supporting); Salomon AL: conceptualization (supporting), data curation (supporting), writing-original draft (supporting), writing-review and editing (supporting); Silva HEC: conceptualization (supporting), data curation (supporting), funding acquisition (supporting), methodology (supporting), writing-original draft (supporting); Lombardi Júnior I: writing-review and editing (supporting); Peccin MS: writing-review and editing (supporting); Amorim FF: writing-original draft (supporting), writing-review and editing (supporting); Santana LA: writing-review and editing (supporting). All authors read and approved the final manuscript.

Corresponding author

Correspondence to Aline Mizusaki Imoto.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Imoto, A.M., Gottems, L.B., Salomon, A.L. et al. The impact of a low-calorie, low-glycemic diet on systemic lupus erythematosus: a systematic review. Adv Rheumatol 61, 66 (2021). https://doi.org/10.1186/s42358-021-00224-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s42358-021-00224-1

Keywords